Tonix Pharmaceuticals
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Tonix Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#668 of 15,742 sponsors by registered trial count).
Tonix Pharmaceuticals: 23 sponsored US clinical trials, 1 recruiting.
Tonix Pharmaceuticals sponsors 23 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 16 completed. 11 of these trials are in Phase 3-4 (later-stage) and 12 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is PTSD, with 2 trials.
Top-decile sponsor footprint
Tonix Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#668 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
16 of 22 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (72.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
23 total, page 1 of 1
A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
NCT07621237
Comparing Efficacy & Safety Of TNX-1300 To Placebo With UC For Treatment Of Acute Cocaine Intoxication In ED Subjects (CATALYST)
NCT06045793
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TNX-1500 in Healthy Subjects
NCT07473752
Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD)
NCT05686408
A Study to Evaluate the Efficacy and Safety of TNX-1900 in Patients With Chronic Migraine
NCT05679908
A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection
NCT05472090
A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With Fibromyalgia
NCT05273749
A Single-Dose, Randomized, Open-Label, 2-Way Crossover Study to Evaluate the Dose-Proportionality, Safety, and Tolerability of TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets) in Healthy Japanese and Chinese Subjects
NCT07464535
Assessment of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 Peptide Antigens
NCT05216510
A Phase 3 Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia
NCT04508621
A Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia
NCT04172831
A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD
NCT03841773
A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD
NCT03508700
12-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients
NCT03110575
Safety and Efficacy Study of TNX-102 SL in Patients With Military-related PTSD
NCT03062540
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
NCT02829814
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
NCT02589275
Safety and Efficacy Study of TNX-201 Capsules for Treatment of Single Tension-Type Headache
NCT02423408
Open Label Extension Safety and Efficacy Study of TNX-102 SL Tablets in Military Related PTSD and Related Conditions
NCT02421679
A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia
NCT02436096
Safety and Efficacy Study of TNX-102 SL in Subjects With Military-Related PTSD and Related Conditions
NCT02277704
12-Month Open-Label Long-term Safety Study of TNX-102 SL Tablets in Fibromyalgia Patients
NCT02015234
BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BESTFIT)
NCT01903265
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 9 |
| Phase 3 | 11 |
Therapeutic Areas
What is open in the Tonix Pharmaceuticals pipeline
1 recruiting of 23 indexed (4% open); 16 completed (70%).
Phase mix: 11 late (III/IV) vs 12 early (I/II) (balanced across stages).
Top condition: PTSD (2 trials), 7 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Tonix Pharmaceuticals: open-pipeline peers nationwide
Peers matched on 23 registered trials and 4% open enrollment, not the therapeutic-area sidebar.
Tonix Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 23 trials (± recruiting share)
- AMAG Pharmaceuticals · 23 trials · 9% recruiting
- AtriCure · 23 trials · 22% recruiting
- Cara Therapeutics · 23 trials · 0% recruiting
- Craig L Slingluff, Jr · 23 trials · 4% recruiting
Sponsors near 4% open enrollment (± trial volume)
- Esperion Therapeutics · 4% recruiting · 23 trials
- Rockefeller University · 4% recruiting · 117 trials
- Galderma R&D · 4% recruiting · 158 trials
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · 4% recruiting · 45 trials
Related
What to do with this Tonix Pharmaceuticals page
23 registered trials is a research-attention snapshot, not an endorsement of Tonix Pharmaceuticals or any single study.
- 1 of Tonix Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- PTSD is the condition Tonix Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See PTSD trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Tonix Pharmaceuticals pipeline card: 23 registered trials from official public datasets.Report a data error.